Undisclosed Claudin18.2 mRNA cancer vaccine / Moderna - LARVOL DELTA

Moderna reveals Claudin18.2 ambitions via cancer vaccine, solid tumor CAR-T combo plans (FierceBiotech) - "That sounds like the plan, according to CARsgen Therapeutics. The Chinese biotech is developing CT041, also known as satricabtagene autoleucel, as a Claudin18.2-focused CAR-T for the potential treatment of gastric, pancreatic and other digestive system cancers....The biotech said it has initiated a collaboration agreement with Moderna for the two companies to 'contemplate conducting preclinical studies and a phase 1 clinical trial to evaluate CT041 in combination with Moderna’s Claudin18.2 mRNA cancer vaccine.'"

Licensing / partnership • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor